AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$EVH

McCarthy Daniel Joseph sold $329K of EVH

McCarthy Daniel Joseph (PRESIDENT) sold 65,892 shares of Evolent Health, Inc. (EVH) at $5.00 ($0.33M total) on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McCarthy Daniel Joseph
Published Aug 28, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EVH
Neutral
high confidence
Mentioned
$EVH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVHNeutralLow
01

Why it matters

Limited impact on EVH stock; the transaction size is modest and pre‑planned.

02

Market read

Routine insider sale with negligible market effect.

03

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing the informational content of the transaction.

Relevance 3/10Novelty 4/10Timing: filed Aug 28 2026

Background

Form 4 filings disclose insider trades; this is a routine sale by the company president.

Company-level read

Ticker impact

$EVHNeutralHigh confidence
Context

President Daniel Joseph McCarthy sold 65,892 shares of EVH for $329,460 via a 10b5‑1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to float and disclosed via routine Form 4; no immediate market reaction expected.

Counterpoint

What could challenge this read

Some traders may view any insider sale as a bearish signal despite the small amount.

Key entities

  • Company
    Evolent Health, Inc.

    US‑listed health‑tech firm (ticker EVH).

  • Individual
    Daniel Joseph McCarthy

    President of EVH, insider selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EVH insider trading history →

Related articles

AUG 13
$EVHMedAI 8/10

Evolent Health (EVH) Q2 2026 Earnings Call Transcript

Evolent Health (EVH) reported Q2 2026 revenue of $652.5M versus $444.3M a year earlier, citing the Highmark contract launch. Net loss attributable to common shareholders was $28.4M. Adjusted EBITDA was $28.1M. Full-year 2026 revenue guidance was raised to $2.6B-$2.7B and adjusted EBITDA to $120M-$135M. 2027 revenue growth is expected to exceed 25%.

fool.com7 min
AUG 8
$EVHMed

Evolent Health Q2 Earnings Call Highlights

Evolent Health (EVH) reported Q2 call highlights. Management said its Aetna partnership continued producing clinical engagement above targets, while claims-based results met expectations. For 3Q-4Q, revenue is expected to be meaningfully above Q2 on Performance Suite. Evolent signed an oncology Performance Suite deal expected to add about $300M annualized revenue, and expects 2027 revenue growth over 25% and 2027 adj. EBITDA midpoint at or above $150M.

finance.yahoo.com5 min
AUG 7
$EVHMed

EVH Q2 2026 Deep Dive: Oncology Suite and AI Automation Drive Growth Amid Membership Headwinds

Evolent Health (EVH) reported Q2 CY2026 revenue of $652.5 million, up 46.9% year on year, beating Wall Street expectations. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ estimates. Non-GAAP EPS was $0.02. Management cited Highmark contract launch, renewals, and scaling of its Auth Intelligence AI automation, while noting Medicaid and exchange membership headwinds.

stockstory.org6 min
AUG 6
$EVHMedAI 8/10

Why is Evolent Health stock surging today?

Evolent Health (EVH) shares rose 23.4% in pre-market after the company reported Q2 2026 results. According to the article, EPS was $0.02 versus -$0.01 expected, and revenue was $652.52M versus $597.46M expected, up about 47% year over year. The move was linked to short interest with days to cover near 5.67 and multiple EPS estimate revisions.

investing.com2 min